Dynavax Technologies Corporation
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Dynavax Technologies Corporation sits in the top decile of US sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count).
Dynavax Technologies Corporation: 16 sponsored US clinical trials, 1 recruiting.
Dynavax Technologies Corporation sponsors 16 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 11 completed. 3 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis, with 1 trials.
Top-decile sponsor footprint
Dynavax Technologies Corporation ranks in the top decile of sponsors by registered trial count (#886 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
11 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (73.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
16 total, page 1 of 1
Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age
NCT07207408
Trial of the Immunogenicity, Safety, and Tolerability of rF1V Vaccine With CpG 1018® Adjuvant Compared With rF1V Vaccine in Adults 18 to 55 Years of Age
NCT05506969
HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis
NCT03934736
Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC
NCT03326752
A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT02521870
Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
NCT02266147
Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine
NCT02117934
A Study of the Immune Response to Heplisav in Healthy Older Adults
NCT01999699
Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease
NCT01282762
Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine
NCT01005407
Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients
NCT00985426
Safety, Pharmacokinetics, and Pharmacodynamics of SD-101 in Healthy Normal Males
NCT00599001
Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine
NCT00511095
A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer
NCT00403052
Efficacy and Safety Study of TOLAMBA™ in Ragweed-Allergic Adults
NCT00387738
Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients
NCT00426712
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 4 |
| Phase 3 | 3 |
What is open in the Dynavax Technologies Corporation pipeline
1 recruiting of 16 indexed (6% open); 11 completed (69%).
Phase mix: 3 late (III/IV) vs 12 early (I/II) (early-phase heavy).
Top condition: Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Dynavax Technologies Corporation: open-pipeline peers nationwide
Peers matched on 16 registered trials and 6% open enrollment, not the therapeutic-area sidebar.
Dynavax Technologies Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 16 trials (± recruiting share)
- Accelerated Community Oncology Research Network · 16 trials · 0% recruiting
- Altimmune · 16 trials · 6% recruiting
- American University · 16 trials · 13% recruiting
- Anthera Pharmaceuticals · 16 trials · 0% recruiting
Sponsors near 6% open enrollment (± trial volume)
- Albert Einstein Healthcare Network · 6% recruiting · 48 trials
- Bassett Healthcare · 6% recruiting · 16 trials
- East Tennessee State University · 6% recruiting · 16 trials
- Monell Chemical Senses Center · 6% recruiting · 16 trials
Related
What to do with this Dynavax Technologies Corporation page
16 registered trials is a research-attention snapshot, not an endorsement of Dynavax Technologies Corporation or any single study.
- 1 of Dynavax Technologies Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis is the condition Dynavax Technologies Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Dynavax Technologies Corporation pipeline card: 16 registered trials from official public datasets.Report a data error.